Vom Kompetenznetz Hepatitis (HepNet) zur Deutschen Leberstiftung

详细信息    查看全文

• 作者：S. Hardtke ; B. Wiebner…
• 关键词：Network of competence for viral hepatitis ; German liver foundation ; HepNet study ; house ; Liver disease ; Investigator initiated trials/registries
• 刊名：Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：59
• 期：4
• 页码：482-488
• 全文大小：360 KB
• 参考文献：1.Cornberg M et al (2011) Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection – The German Guideline. Z Gastroenterol 49(7):871–930CrossRef PubMed
  2.Wedemeyer H et al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364(4):322–331CrossRef PubMed
  3.Yurdaydin C et al (2012) Pegylated-interferon-a-2a plus Tenofovir or placebo for the treatment of hepatitis delta: first results of the HIDIT-2 study. Hepatology 56(203a):202a
  4.Jaeckel E et al (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345(20):1452–1457CrossRef PubMed
  5.Wiegand J et al (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43(2):250–256CrossRef PubMed
  6.Deterding K et al (2013) Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 13(6):497–506CrossRef PubMed
  7.Sarrazin C et al (2010) Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection. Z Gastroenterol 48(2):289–351CrossRef PubMed
  8.Dintsios CM et al (2010) Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol 22(3):278–288CrossRef PubMed
  9.Vogel M et al (2009) Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large german networks on the study of acute HCV infection. Clin Infect Dis 49(2):317–319. doi:10.1086/600058CrossRef PubMed
  10.Deterding K et al (2009) The german hep-net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 47(6):531–540CrossRef PubMed
  11.Wiegand J et al (2007) Fate and function of hepatitis-C-virus-specific T‑cells during peginterferon-alpha 2b therapy for acute hepatitis C. Antivir Ther (Lond) 12(3):303–316
  12.Wiegand J et al (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43(2):250–256CrossRef PubMed
  13.Wiegand J et al (2004) Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 40(1):98–107CrossRef PubMed
  14.Friedrich-Rust M et al (2012) Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. Hepatology 56:840aCrossRef
  15.Wiese M et al (2014) Evaluation of liver disease progression in the german hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 59(1):49–57CrossRef PubMed
  16.Heidrich B et al (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60(1):87–97CrossRef PubMed
  17.Sarrazin C et al (2011) Improved responses to Pegylated interferon alfa-2b and Ribavirin by individualizing treatment for 24–72 weeks. Gastroenterology 141(5):1656–1664CrossRef PubMed
  18.Berg T et al (2009) Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1‑infected patients. Hepatology 50(2):369–377CrossRef PubMed
  19.Heidrich B et al (2014) reatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PloS One 9(10):p. e108751CrossRef
  20.von Wagner M et al (2008) Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology 48(5):1404–1411CrossRef
  21.Manns MP, von Hahn T (2013) Novel therapies for hepatitis C – one pill fits all? Nat Rev Drug Discov 12(8):595–610CrossRef PubMed
  22.Manns MP, Cornberg M (2013) Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 13(5):378–379CrossRef PubMed
  23.Wedemeyer H et al (2014) Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21(Suppl 1):60–89CrossRef PubMed
  24.Razavi H et al (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 21(Suppl 1):34–59CrossRef PubMed
  
• 作者单位：S. Hardtke (1)
  B. Wiebner (1)
  Univ.-Prof. M. P. Manns (1)
  
  1. Deutsche Leberstiftung, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  General Practice and Family Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1437-1588

文摘

The competence network for viral hepatitis (HepNet) was founded in 2002 with funding from the German government and has influenced the research on viral hepatitis in Germany. HepNet collaborator sites have been involved in numerous national and international investigator-initiated, as well as industry-sponsored, phase 1–3 studies. Within the HepNet Study-House, many groundbreaking investor-initiated trials have been completed and are still ongoing. For example, the acute hepatitis C trials and trials on chronic hepatitis D (delta), which led to therapy optimization. Continuation of the competence network on viral hepatitis has been achieved by the foundation of the German Liver Foundation, which has been an external cooperation partner of the German Center for Infection Research (DZIF) for two years. The well-established HepNet Study-House acts here as the clinical trial platform for all DZIF hepatitis trials.